COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ADULT PATIENTS UNDERGOING ELECTIVE HIP OR KNEE REPLACEMENT SURGERY IN PORTUGAL
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.25756/rpf.v6i1.34 |
Resumo: | A cost-effectiveness model was developed in order to evaluate the costs and consequences of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism in adult patients undergoing hip or knee replacement surgery. This analysis was run from the societal perspective, over a five-year time horizon in the Portuguese setting. A five percent discount rate was applied to both costs and consequences. The model is divided into three modules: prophylaxis, post-prophylaxis and long-term complications. Transition probabilities were based on the RECORD-1 and RECORD-3 clinical trials, which compared rivaroxaban 10 mg once-daily (OD) with enoxaparin 40 mg OD, and published literature. Sensitivity analyses were performed in order to evaluate the robustness and uncertainty of the model. The results obtained suggest that rivaroxaban 10 mg OD, started six to ten hours after surgery, is a dominant strategy versus enoxaparin 40 mg OD, started on the evening before the surgery. The use of rivaroxaban in this therapeutic indication provides the efficient use of the scarce resources since it’s associated with better clinical outcomes at a lower cost. |
id |
RCAP_0ac853c5c1c2a50b5a9ae7a143ed1d1e |
---|---|
oai_identifier_str |
oai:ojs.farmacoterapia.pt:article/34 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ADULT PATIENTS UNDERGOING ELECTIVE HIP OR KNEE REPLACEMENT SURGERY IN PORTUGALCUSTO-EFECTIVIDADE QUE COMPARA OS CUSTOS E CONSEQUÊNCIAS ASSOCIADOS A RIVAROXABANO RELATIVAMENTE A ENOXAPARINA NA PREVENÇÃO DO TROMBOEMBOLISMO VENOSO EM DOENTES ADULTOS SUBMETIDOS A ARTOPLASTIA ELETIVA DA ANCA OU JOELHOA cost-effectiveness model was developed in order to evaluate the costs and consequences of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism in adult patients undergoing hip or knee replacement surgery. This analysis was run from the societal perspective, over a five-year time horizon in the Portuguese setting. A five percent discount rate was applied to both costs and consequences. The model is divided into three modules: prophylaxis, post-prophylaxis and long-term complications. Transition probabilities were based on the RECORD-1 and RECORD-3 clinical trials, which compared rivaroxaban 10 mg once-daily (OD) with enoxaparin 40 mg OD, and published literature. Sensitivity analyses were performed in order to evaluate the robustness and uncertainty of the model. The results obtained suggest that rivaroxaban 10 mg OD, started six to ten hours after surgery, is a dominant strategy versus enoxaparin 40 mg OD, started on the evening before the surgery. The use of rivaroxaban in this therapeutic indication provides the efficient use of the scarce resources since it’s associated with better clinical outcomes at a lower cost.Foi desenvolvido um modelo de custo-efetividade que compara os custos e consequências associados a rivaroxabano relativamente a enoxaparina na prevenção do tromboembolismo venoso em doentes adultos submetidos a artoplastia eletiva da anca ou joelho. Esta análise foi desenvolvida na perspectiva da sociedade, ao longo de um horizonte temporal de cinco anos, no contexto português. Foi aplicada uma taxa de atualização de cinco por cento para custos e consequências. O modelo divide-se em três módulos: profilaxia, pós-profilaxia e complicações a longo prazo. As probabilidades de transição são baseadas no programa de ensaios clínicos RECORD e literatura publicada. Foi efetuada análise de sensibilidade com os objetivos de avaliar a robustez e incerteza do modelo. Os resultados sugerem que rivaroxabano, na posologia 10 mg, administrado uma vez por dia, iniciado nas seis a dez horas seguintes à intervenção cirúrgica, constitui uma alternativa dominante relativamente a enoxaparina, na posologia 40 mg, administrado uma vez por dia, iniciada na véspera da intervenção cirúrgica. A utilização de rivaroxabano nesta indicação terapêutica contribui para a utilização eficiente dos recursos escassos, dado que permite a obtenção de melhores resultados clínicos a um menor custo.Formifarma2014-03-26info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.25756/rpf.v6i1.34https://doi.org/10.25756/rpf.v6i1.34Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 6 No 1 (2014): Janeiro; 13-20Revista Portuguesa de Farmacoterapia; v. 6 n. 1 (2014): Janeiro; 13-202183-73411647-354Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttp://revista.farmacoterapia.pt/index.php/rpf/article/view/34http://revista.farmacoterapia.pt/index.php/rpf/article/view/34/26Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapiahttp://creativecommons.org/licenses/by-nc-nd/4.0info:eu-repo/semantics/openAccessRoxo Neves, JoséFolkerts, KerstinUmbelino, SofiaFonseca Santos, Isabel2023-09-01T04:33:01Zoai:ojs.farmacoterapia.pt:article/34Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:11:30.761453Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ADULT PATIENTS UNDERGOING ELECTIVE HIP OR KNEE REPLACEMENT SURGERY IN PORTUGAL CUSTO-EFECTIVIDADE QUE COMPARA OS CUSTOS E CONSEQUÊNCIAS ASSOCIADOS A RIVAROXABANO RELATIVAMENTE A ENOXAPARINA NA PREVENÇÃO DO TROMBOEMBOLISMO VENOSO EM DOENTES ADULTOS SUBMETIDOS A ARTOPLASTIA ELETIVA DA ANCA OU JOELHO |
title |
COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ADULT PATIENTS UNDERGOING ELECTIVE HIP OR KNEE REPLACEMENT SURGERY IN PORTUGAL |
spellingShingle |
COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ADULT PATIENTS UNDERGOING ELECTIVE HIP OR KNEE REPLACEMENT SURGERY IN PORTUGAL Roxo Neves, José |
title_short |
COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ADULT PATIENTS UNDERGOING ELECTIVE HIP OR KNEE REPLACEMENT SURGERY IN PORTUGAL |
title_full |
COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ADULT PATIENTS UNDERGOING ELECTIVE HIP OR KNEE REPLACEMENT SURGERY IN PORTUGAL |
title_fullStr |
COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ADULT PATIENTS UNDERGOING ELECTIVE HIP OR KNEE REPLACEMENT SURGERY IN PORTUGAL |
title_full_unstemmed |
COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ADULT PATIENTS UNDERGOING ELECTIVE HIP OR KNEE REPLACEMENT SURGERY IN PORTUGAL |
title_sort |
COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ADULT PATIENTS UNDERGOING ELECTIVE HIP OR KNEE REPLACEMENT SURGERY IN PORTUGAL |
author |
Roxo Neves, José |
author_facet |
Roxo Neves, José Folkerts, Kerstin Umbelino, Sofia Fonseca Santos, Isabel |
author_role |
author |
author2 |
Folkerts, Kerstin Umbelino, Sofia Fonseca Santos, Isabel |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Roxo Neves, José Folkerts, Kerstin Umbelino, Sofia Fonseca Santos, Isabel |
description |
A cost-effectiveness model was developed in order to evaluate the costs and consequences of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism in adult patients undergoing hip or knee replacement surgery. This analysis was run from the societal perspective, over a five-year time horizon in the Portuguese setting. A five percent discount rate was applied to both costs and consequences. The model is divided into three modules: prophylaxis, post-prophylaxis and long-term complications. Transition probabilities were based on the RECORD-1 and RECORD-3 clinical trials, which compared rivaroxaban 10 mg once-daily (OD) with enoxaparin 40 mg OD, and published literature. Sensitivity analyses were performed in order to evaluate the robustness and uncertainty of the model. The results obtained suggest that rivaroxaban 10 mg OD, started six to ten hours after surgery, is a dominant strategy versus enoxaparin 40 mg OD, started on the evening before the surgery. The use of rivaroxaban in this therapeutic indication provides the efficient use of the scarce resources since it’s associated with better clinical outcomes at a lower cost. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-03-26 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.25756/rpf.v6i1.34 https://doi.org/10.25756/rpf.v6i1.34 |
url |
https://doi.org/10.25756/rpf.v6i1.34 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
http://revista.farmacoterapia.pt/index.php/rpf/article/view/34 http://revista.farmacoterapia.pt/index.php/rpf/article/view/34/26 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapia http://creativecommons.org/licenses/by-nc-nd/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapia http://creativecommons.org/licenses/by-nc-nd/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Formifarma |
publisher.none.fl_str_mv |
Formifarma |
dc.source.none.fl_str_mv |
Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 6 No 1 (2014): Janeiro; 13-20 Revista Portuguesa de Farmacoterapia; v. 6 n. 1 (2014): Janeiro; 13-20 2183-7341 1647-354X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799129985446838272 |